SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 17, 2011 08:16 ET

Cheap Valuations for Dendreon and BioSante Spark Investor Interest

The Paragon Report Provides Equity Research on Dendreon & BioSante Pharmaceuticals

NEW YORK, NY--(Marketwire - Nov 17, 2011) - Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper Inc. healthcare and biotechnology stock funds are up 17 percent this year and 35 percent over the past 12 months. Healthcare stocks underperformed during last year's market rally, and Andy Oh, research analyst and portfolio manager of the Fidelity Select Pharmaceuticals Fund argues that investors are embracing the "cheap valuations in health care stocks." The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN) and BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). Access to the full company reports can be found at:

www.paragonreport.com/DNDN

www.paragonreport.com/BPAX

The increase in M&A activity in the healthcare sector is yet another reason investors are once again taking a close look at biotech stocks. Michael Gregory, portfolio manager of the Highland Long/Short Health care Fund argues that "acquisitions are needed to fuel growth" as government intervention suppresses growth in larger firms. Moreover, Big Pharma companies are about to face the largest patent expiration cliff in the industry's history and will need to fill the gap of lost income.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters

Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation, and has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers.

Dendreon Corporation engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. Dendreon's first product, PROVENGE, was approved by the FDA in April 2010. Shares of the company have been battered in recent months as the company said it expects much slower growth and said concerns about government reimbursement are hurting sales. In response to the disappointing sales, the company said in September that it would eliminate 500 jobs, or more than 25 percent of its work force, to help reduce costs.

Currently, Biosante Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio of cancer vaccines in development. The company believes that "cancer vaccines are an increasingly exciting option for cancer treatment, especially after the FDA approval of Provenge for the treatment of prostate cancer in April 2010."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer